Surgery, Gastroenterology and Oncology
Vol. 22, No. 2, June 2017
Assessment of Hyperfibrinolysis in Cirrhotic Patients Undergoing Orthotopic Liver Transplantation. A Retrospective Observational Study
Ecaterina Scarlatescu, Ana M Buruiana, Gabriela Droc, Dana R Tomescu
ORIGINAL PAPER, June 2017
Article DOI: 10.21614/jtmr-22-2-118
Introduction: Prophylactic antifibrinolytics are recommended for patients at risk to develop significant hyperfibrinolysis during liver transplantation, identified by the preoperative thromboelastometry. Even with this approach, postreperfusion hyperfibrinolysis is frequent, often leading to increased bleeding and transfusion requirements.The aim of this study was to assess hyperfibrinolysis and to predict postreperfusion hyperfibrinolysis based on preoperative standard coagulation tests (SCTs) and thromboelastometry in liver transplant patients without an indication for antifibrinolytic prophylaxis and or therapy until graft reperfusion.

Methods: The study group included cirrhotic patients undergoing orthotopic liver transplantation. Preoperative and at 10 minutes after graft reperfusion, the following data were recorded for each patient: SCTs, complete blood counts and rotation thromboelastometry (ROTEM, TEM International GmbH, Munich, Germany). From ROTEM measurements we used standard parameters and indices calculated from the first derivative of the clot firmness curve. Hyperfibrinolysis was defined as maximum lysis >15% in EXTEM or by an increase in MCF in APTEM compared to EXTEM (DMCF) more than 7% of EXTEM MCF.

Results: Using ML>15% preoperative and postreperfusion hyperfibrinolysis were identified in 20% and 22 % of the patients and were not correlated with SCTs, fibrinogen levels, platelet number, with clot amplitude or thrombus formation on ROTEM.Using DMCF criteria, preoperative hyperfibrinolysis was present in 34% of the patients and was associated with decreased thrombus formation (AUC, p=0.021) and decreased clot elasticity in EXTEM (p=0.01). When DMCF criteria was used postreperfusion, hyperfibrinolysis was present in 42% of the patients, could not be correlated with preoperative ROTEM standard or derived parameters and was associated with decreased MCF in EXTEM and FIBTEM (p= 0.04 and 0.006) and delayed and decreased thrombus formation.

Conclusions: The reported incidence of hyperfibrinolysis in cirrhotic patients before and during liver transplantation depends on the ROTEM-based definition used. The difference between APTEM and EXTEM identifies more patients with hyperfibrinolysis than ML>15% criteria and was associated with a decrease in thrombus formation and elasticity both preoperative and post graft reperfusion.

Full Text Sources: Download pdf
Abstract:   Abstract EN
Views: 2611


Watch Video Articles


For Authors



Journal Subscriptions

Current Issue

Dec 2025

Supplements

Instructions for authors
Online submission
Contact
ISSN: 2559 - 723X (print)

e-ISSN: 2601 - 1700 (online)

ISSN-L: 2559 - 723X

Journal Abbreviation: Surg. Gastroenterol. Oncol.

Surgery, Gastroenterology and Oncology (SGO) is indexed in:
  • SCOPUS
  • EBSCO
  • DOI/Crossref
  • Google Scholar
  • SCImago
  • Harvard Library
  • Open Academic Journals Index (OAJI)

Open Access Statement

Surgery, Gastroenterology and Oncology (SGO) is an open-access, peer-reviewed online journal published by Celsius Publishing House. The journal allows readers to read, download, copy, distribute, print, search, or link to the full text of its articles.

Journal Metrics

Time to first editorial decision: 25 days
Rejection rate: 61%
CiteScore: 0.2



Meetings and Courses in 2025
Meetings and Courses in 2024
Meetings and Courses in 2023
Meetings and Courses in 2022
Meetings and Courses in 2021
Meetings and Courses in 2020
Meetings and Courses in 2019
Verona expert meeting 2019

Creative Commons License
Surgery, Gastroenterology and Oncology applies the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits readers to copy and redistribute the material in any medium or format, remix, adapt, build upon the published works non-commercially, and license the derivative works on different terms, provided the original material is properly cited and the use is non-commercial. Please see: https://creativecommons.org/licenses/by-nc/4.0/
Publisher’s Note:
The opinions, statements, and data contained in article are solely those of the authors and not of Surgery, Gastroenterology and Oncology journal or the editors. Publisher and the editors disclaim responsibility for any damage resulting from any ideas, instructions, methods, or products referred to in the content.